Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

CRISPR Therapeutics AG CRSP shares moved lower Tuesday after the biotechnology company outlined plans to raise capital through a new convertible debt offering. The gene-editing firm said it intends to ...

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

CRISPR Therapeutics (NASDAQ: CRSP) is a company that can potentially help revolutionize healthcare. Its gene-editing therapies can be game changers for patients living with illnesses and conditions ...

If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...

Casgevy is starting to build some serious sales momentum. CRISPR Therapeutics also has a deep pipeline and healthy funding. The stock requires patience, but there is a visible path to a bright future.

Crispr Therapeutics remains highly volatile, disconnected from near-term fundamentals, yet I see long-term value far above current levels. CRSP's business progress is slow, with pipeline milestones ...

Gene therapy and gene editing are marvels of modern biotechnology, providing revolutionary techniques for fixing genetic abnormalities. Gene therapy introduces functional genetic material to ...

Wood's thesis is built on the combination of artificial intelligence and programmable biology. Earlier this year, Wood highlighted the transformative potential of AI in health care, calling it the ...